Table 1.

Commonly used breast cancer xenograft models

Human breast cancer xenograft model	Description	Reference
MCF-7	Breast adenocarcinoma cell line, oestrogen receptor-positive	[37]
MCF-7/6	Oestrogen sensitive	[38]
MCF-7 BAG	Immunodeficient xenograft model	[39]
MCF-7/hVEGF	hVEGF overexpressing
MCF-7-TAM LT	Long-term tamoxifen-stimulated breast tumour model	[40]
MCF-7/neu	Overexpressing oncogene neu	[41]
MCF-7-MIII	Oestrogen sensitive	[42]
MCF-7Ca	Transfected with human aromatase gene	[43]
MT2	MCF-7 tamoxifen-stimulated tumour with Asp351Tyr mutant oestrogen receptor	[44]
MT2 TAM	MCF-7-derived tumour serially passaged with tamoxifen	[40]
MT-1	Oestrogen and progesterone receptor-negative in nude rats	[45]
MT-3	Oestrogen receptor-negative	[45]
LY2	Anti-oestrogen-resistant variant of MCF-7	[46]
UMB-1Ca	Oestrogen-independent variant of MCF-7	[47]
MDA-MB-231	Oestrogen independent	[48]
MDA-MD-231 BAG	Immunodeficient xenograft model	[39]
MDA-MB-361	Brain metastasis-derived breast adenocarcinoma cell line	[49]
MDA-MB-435	Oestrogen receptor-negative	[48]
MDA-MB-435A	Ascites model	[50]
MDA-MB-435S	Spindle-shaped strain of parent line	[51]
MDA-MD-435 BAG	Immunodeficient xenograft model	[39]
MDA-MB-453 BAG	Fibroblast growth factor receptor overexpressing	[39]
MDA-453/LCC6		[52]
MDA-MB-468	Oestrogen receptor-negative metastasis-derived cell line	[49]
MDA-MB-453	Breast adenocarcinoma cell line	[53]
MCF10AT	Preneoplastic and proliferative model; nontumourigenic	[54]
MCF10AneoN	Transfected with neomycin-resistance gene	[55]
MCF10AneoT	T24-Ha-ras-transformed derivative of MCF10A	[55]
MCF10DCIS.com	Comedo ductal carcinoma in situ	[56]
MC-2		[57]
MC-5		[57]
MC-18		[57]
SK-BR3	Breast adenocarcinoma cell line that overexpresses oncogenic protein p185HER2; oestrogen receptor-negative	[58]
SK-BR3/hVEGF	VEGF overexpressing cell line	[58]
BT-20	Oestrogen receptor-negative	[37]
BT-474	Erb2 overexpressing breast tumour	[59]
ZR-75-1	Oestrogen-dependent breast carcinoma	[60]
SUM149	Inflammmatory breast cancer cell line	[61]
SUM159PT	Oestrogen independent	[62]
T47D	Oestrogen receptor-positive	[63]
T47D-E2	Tamoxifen naïve tumour	[63]
KPL-1	Oestrogen receptor-positive	[64]
KPL-4	Oestrogen receptor-negative	[65]
MaTu	Oestrogen receptor-negative solid human mammary carcinoma cell line	[45]
MC4000	Oestrogen receptor-negative	[45]
HT-39	Oestrogen receptor-negative	[66]
HX99		[67]
T61	Oestrogen receptor-positive ductal carcinoma	[68]
B37		[69]
BO	Oestrogen receptor-positive	[70]
Br10		[71]
SE		[71]
WIBC-9	Inflammmatory breast cancer cell line	[57]
Met-1	Metastatic breast cancer cell line
MAXF401		[72]
MX-1		[73]
MAXF 499	Solid ductal	[74]
NCI/ADR or MCF-7/ADR	Multidrug-resistant MCF-7 cell line that overexpresses P-glycoprotein	[75]
4296	Oestrogen receptor-positive	[76]
4049	Oestrogen receptor-negative	[76]
4151		[75]
4134		[75]
3366		[77]
4000		[77]
CAL51	Metastatic model of adenocarcinoma	[78]
MA-11	Oestrogen and progesterone negative receptor in nude rats	[79]
H31		[80]
MARY-X	Inflammatory breast cancer model	[81]
HBT 3477	Adenocarcinoma	[82]
Hs578T	Carcinosarcoma derived, epithelial in origin	[82]
C8161	Breast cancer line with high levels of spontaneous metastasis	[83]
M24met	Breast cancer line with high levels of spontaneous metastasis	[83]
CaMa 15	Primary infiltrating ductal breast carcinoma	[37]
MaNo 4	Medullary breast carcinoma	[37]
GI-101	Metastatic breast tumour line	[25]
UISO-BCA-NMT-18	Primary breast carcinoma	[84]

VEGF, vascular endothelial growth factor.